In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, BioNexus Gene Lab Corp (NASDAQ: BGLC) closed at $0.60 down -29.32% from its previous closing price of $0.85. In other words, the price has decreased by -$29.32 from its previous closing price. On the day, 0.72 million shares were traded. BGLC stock price reached its highest trading level at $0.7075 during the session, while it also had its lowest trading level at $0.58.
Ratios:
For a deeper understanding of BioNexus Gene Lab Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.24 and its Current Ratio is at 4.93. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BGLC now has a Market Capitalization of 10597086 and an Enterprise Value of 4801123. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.09 while its Price-to-Book (P/B) ratio in mrq is 1.10. Its current Enterprise Value per Revenue stands at 0.491 whereas that against EBITDA is -1.913.
Stock Price History:
Over the past 52 weeks, BGLC has reached a high of $17.88, while it has fallen to a 52-week low of $0.31. The 50-Day Moving Average of the stock is -18.10%, while the 200-Day Moving Average is calculated to be -54.81%.
Shares Statistics:
For the past three months, BGLC has traded an average of 1.54M shares per day and 432500 over the past ten days. A total of 17.67M shares are outstanding, with a floating share count of 7.07M. Insiders hold about 60.27% of the company’s shares, while institutions hold 0.59% stake in the company. Shares short for BGLC as of 1711584000 were 43358 with a Short Ratio of 0.03, compared to 1709164800 on 50314. Therefore, it implies a Short% of Shares Outstanding of 43358 and a Short% of Float of 0.25.
Earnings Estimates
The stock of BioNexus Gene Lab Corp (BGLC) is currently being evaluated by BKLC analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $19.94, with high estimates of $25.32 and low estimates of $7.71.
